Perspective Therapeutics, Inc. (NYSE:CATX) put the best spin possible on phase I/II data for its radiopharmaceutical VMT-α-NET but at the end of the day the drug only achieved a confirmed response in 1 out of 9 patients in an open-label trial. The company’s stock crashed ~50% on the news announced on November 21, 2024.